ATE402256T1 - Antitumoraktivität zeigendes runx3-gen und dessen verwendung - Google Patents
Antitumoraktivität zeigendes runx3-gen und dessen verwendungInfo
- Publication number
- ATE402256T1 ATE402256T1 AT01902862T AT01902862T ATE402256T1 AT E402256 T1 ATE402256 T1 AT E402256T1 AT 01902862 T AT01902862 T AT 01902862T AT 01902862 T AT01902862 T AT 01902862T AT E402256 T1 ATE402256 T1 AT E402256T1
- Authority
- AT
- Austria
- Prior art keywords
- runx3
- development
- cancer
- present
- runx3 gene
- Prior art date
Links
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 title abstract 4
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 101100476219 Homo sapiens RUNX3 gene Proteins 0.000 abstract 4
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 3
- 230000007067 DNA methylation Effects 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 108091029523 CpG island Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 238000003782 apoptosis assay Methods 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 230000014200 hypermethylation of CpG island Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005522 programmed cell death Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2001-0004018A KR100475649B1 (ko) | 2001-01-29 | 2001-01-29 | 항암활성을 나타내는 ｒｕｎｘ３ 유전자 및 그의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402256T1 true ATE402256T1 (de) | 2008-08-15 |
Family
ID=19705043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01902862T ATE402256T1 (de) | 2001-01-29 | 2001-01-30 | Antitumoraktivität zeigendes runx3-gen und dessen verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7368255B2 (de) |
| EP (1) | EP1356030B1 (de) |
| JP (1) | JP4018542B2 (de) |
| KR (1) | KR100475649B1 (de) |
| AT (1) | ATE402256T1 (de) |
| DE (1) | DE60135022D1 (de) |
| DK (1) | DK1356030T3 (de) |
| ES (1) | ES2310545T3 (de) |
| PT (1) | PT1356030E (de) |
| WO (1) | WO2002061069A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| WO2006057623A1 (en) * | 2004-11-29 | 2006-06-01 | National University Of Singapore | Runx3 antibodies and method of obtaining the antibodies |
| KR100748185B1 (ko) * | 2005-01-31 | 2007-08-10 | 한국생명공학연구원 | Ｌｒｒｃ3ｂ 유전자를 포함하는 항암용 조성물 및 상기유전자를 이용한 진단방법 |
| WO2006096498A2 (en) * | 2005-03-04 | 2006-09-14 | Dana-Farber Cancer Institute, Inc. | Regulation of runx1 for treatment of pain |
| US7611847B2 (en) | 2005-06-01 | 2009-11-03 | Agency For Science, Technology And Research | Method for identifying an intestinal phenotype |
| WO2006132248A1 (ja) * | 2005-06-07 | 2006-12-14 | Daiichi Pharmaceutical Co., Ltd. | Ｒｕｎｘのユビキチン化方法 |
| WO2007081385A2 (en) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| EP2004860A4 (de) * | 2006-03-29 | 2009-12-30 | Wayne John Cancer Inst | Methylierung von östrogenrezeptor-alpha und verwendung |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| EP2530167A1 (de) | 2006-05-11 | 2012-12-05 | Raindance Technologies, Inc. | Mikrofluidische Vorrichtungen |
| EP2077912B1 (de) | 2006-08-07 | 2019-03-27 | The President and Fellows of Harvard College | Fluorkohlenstoffemulsionsstabilisierende tenside |
| WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| EP2198042B1 (de) | 2007-09-17 | 2016-11-02 | MDxHealth SA | Neue marker zum nachweis von blasenkrebs |
| KR20100093523A (ko) * | 2007-11-06 | 2010-08-25 | 주식회사 프로셀제약 | 세포투과성 ｒｕｎｘ３ 재조합 단백질, 이를 코딩하는 폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암 조성물 |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| EP4047367A1 (de) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken |
| EP2320917A4 (de) * | 2008-07-29 | 2011-11-09 | Agency Science Tech & Res | Verfahren zur prävention, hemmung oder umkehrung von tumorgenese und zur identifzierung von verbindungen dafür |
| CN111808084A (zh) * | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| US10520500B2 (en) | 2009-10-09 | 2019-12-31 | Abdeslam El Harrak | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| US10837883B2 (en) | 2009-12-23 | 2020-11-17 | Bio-Rad Laboratories, Inc. | Microfluidic systems and methods for reducing the exchange of molecules between droplets |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| EP4484577A3 (de) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Digitale analytanalyse |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
| EP3412778A1 (de) | 2011-02-11 | 2018-12-12 | Raindance Technologies, Inc. | Verfahren zur bildung gemischter tröpfchen |
| WO2012112804A1 (en) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions and methods for molecular labeling |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| EP3216872B1 (de) | 2011-06-02 | 2020-04-01 | Bio-Rad Laboratories, Inc. | Enzymquantifizierung |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| KR101878451B1 (ko) * | 2011-09-06 | 2018-07-16 | 벤텍스 주식회사 | 약물전달기능을 갖는 언더웨어 |
| WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
| EP2844768B1 (de) | 2012-04-30 | 2019-03-13 | Raindance Technologies, Inc. | Digitale analyse von analyten |
| US9845471B2 (en) | 2013-01-15 | 2017-12-19 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating pancreatic cancer |
| WO2014172288A2 (en) | 2013-04-19 | 2014-10-23 | Raindance Technologies, Inc. | Digital analyte analysis |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| WO2015103367A1 (en) | 2013-12-31 | 2015-07-09 | Raindance Technologies, Inc. | System and method for detection of rna species |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| CN106011263B (zh) * | 2016-06-28 | 2020-01-07 | 宁波大学 | 用于检测与胃癌相关的ndrg4基因甲基化程度的试剂盒及其应用 |
| CA3035882A1 (en) | 2016-07-29 | 2018-02-01 | Kyoto University | Runx inhibitor |
| US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
| KR101994957B1 (ko) | 2017-11-30 | 2019-07-01 | 고려대학교 산학협력단 | Runx3 단백질 또는 이를 코딩하는 runx3 유전자를 포함하는 trail의 항암 효과 증진용 약학 조성물 |
| US20220127570A1 (en) * | 2018-05-03 | 2022-04-28 | Cafa Therapeutics Limited | Immune effector cell and use thereof |
| JP7144037B2 (ja) * | 2018-07-25 | 2022-09-29 | 国立大学法人山口大学 | がんの診断用バイオマーカー |
| WO2020145465A1 (ko) * | 2019-01-08 | 2020-07-16 | 주식회사바이오러넥스 | Runx3 유전자 또는 단백질을 유효성분으로 함유하는 K-Ras 돌연변이 폐암의 예방 또는 치료용 약학 조성물 |
| CN112662764A (zh) * | 2020-03-17 | 2021-04-16 | 博尔诚（北京）科技有限公司 | 一种检测11种癌症的探针组合物 |
| KR102854745B1 (ko) | 2020-04-23 | 2025-09-04 | 진크래프트 주식회사 | R-point 조절 단백질 복합체를 유효성분으로 포함하는 폐암 치료용 약학적 조성물, 상기 복합체의 형성 여부를 이용한 폐암 치료제 스크리닝 방법 및 폐암 진단 방법 |
| US11767541B1 (en) * | 2023-03-27 | 2023-09-26 | Genecraft, Inc. | Adeno-associated virus complex with improved expression of RUNX3 gene and uses for preventing or treating KRAS mutated lung cancer |
-
2001
- 2001-01-29 KR KR10-2001-0004018A patent/KR100475649B1/ko not_active Expired - Fee Related
- 2001-01-30 DK DK01902862T patent/DK1356030T3/da active
- 2001-01-30 JP JP2002561626A patent/JP4018542B2/ja not_active Expired - Fee Related
- 2001-01-30 PT PT01902862T patent/PT1356030E/pt unknown
- 2001-01-30 US US10/466,938 patent/US7368255B2/en not_active Expired - Fee Related
- 2001-01-30 AT AT01902862T patent/ATE402256T1/de not_active IP Right Cessation
- 2001-01-30 DE DE60135022T patent/DE60135022D1/de not_active Expired - Lifetime
- 2001-01-30 WO PCT/KR2001/000121 patent/WO2002061069A1/en not_active Ceased
- 2001-01-30 ES ES01902862T patent/ES2310545T3/es not_active Expired - Lifetime
- 2001-01-30 EP EP01902862A patent/EP1356030B1/de not_active Expired - Lifetime
-
2008
- 2008-03-19 US US12/051,649 patent/US20080261883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1356030A1 (de) | 2003-10-29 |
| WO2002061069A1 (en) | 2002-08-08 |
| US20040146986A1 (en) | 2004-07-29 |
| DE60135022D1 (de) | 2008-09-04 |
| DK1356030T3 (da) | 2008-11-03 |
| KR100475649B1 (ko) | 2005-03-10 |
| JP4018542B2 (ja) | 2007-12-05 |
| ES2310545T3 (es) | 2009-01-16 |
| EP1356030B1 (de) | 2008-07-23 |
| PT1356030E (pt) | 2008-10-30 |
| US20080261883A1 (en) | 2008-10-23 |
| EP1356030A4 (de) | 2005-02-02 |
| KR20020063387A (ko) | 2002-08-03 |
| JP2004529619A (ja) | 2004-09-30 |
| US7368255B2 (en) | 2008-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60135022D1 (de) | Antitumoraktivität zeigendes runx3-gen und dessen verwendung | |
| Batar et al. | DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia | |
| ATE444066T1 (de) | Liganden für den cannabinoidrezeptoren | |
| SG142154A1 (en) | Methods for genomic analysis | |
| NO970626L (no) | Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft | |
| DK0705903T3 (da) | Mutationer i det 17q-koblede bryst- og ovariecancerprædisponeringen | |
| EP1784639A4 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| ATE248175T1 (de) | Epothilonderivate und ihre verwendung als antitumormittel | |
| TR200100047T2 (tr) | Tiyobenzimidazol türevleri | |
| BR0016380A (pt) | Complexo metálico,processo de hidrossililação de olefinas ou de derivados acetilênicos e composição catalìtica | |
| DE50212935D1 (de) | Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen | |
| MXPA04001350A (es) | COMPUESTOS DE FOSFITO NOVEDOSOS Y COMPLEJOS METaLICOS DE FOSFITO NOVEDOSOS. | |
| Dryhurst et al. | Histone H2A. Z deregulation in prostate cancer. Cause or effect? | |
| BR9811589A (pt) | Derivados de hidroxicumaranona o-substituìda como agentes antitumores e antimetastáticos | |
| HUP0101498A1 (hu) | Dexmedetomidin alkalmazása nyugtató hatású gyógyszerkészítmények előállítására | |
| EP0756488A4 (de) | Tumor-suppressor-gen und verfahren zum nachweis von krebs | |
| ATE386742T1 (de) | Imidazonaphthyridine | |
| AU2001233913A1 (en) | Bcmp 84, a protein associated to breast cancer | |
| ATE282607T1 (de) | Tryptase-inhibitoren | |
| Holling et al. | Epigenetic silencing of MHC2TA transcription in cancer | |
| DK1558620T3 (da) | Rutheniumkomplekser med anticancervirkning | |
| HRP20050382B1 (hr) | Novi pirimidin-4,6-dikarboksamidi za selektivnu inhibiciju kolagenaza | |
| IL147890A0 (en) | Pharmaceutical compositions containing pentafluorobenzenesulfonamide derivatives | |
| EP1472375A4 (de) | In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren | |
| ATE406375T1 (de) | Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1356030 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |